2. Search Result
Search Result
Results for "

LTB4 receptor antagonist

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114641A
    BIIL-260 hydrochloride

    		Leukotriene Receptor Inflammation/Immunology
    BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM .
    BIIL-260 hydrochloride
  • HY-15744
    LY255283
    2 Publications Verification

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    LY255283 is a LTB4 receptor (BLT2) antagonist, with an IC50 of ~100 nM for [ 3H]LTB4 binding to guinea pig lung membranes .
    LY255283
  • HY-112741
    SB-209247

    		Leukotriene Receptor Inflammation/Immunology
    SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
    SB-209247
  • HY-149083
    LTB4 antagonist 2

    		Leukotriene Receptor Inflammation/Immunology
    LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
    LTB4 antagonist 2
  • HY-100173
    DW-1350

    		Leukotriene Receptor Inflammation/Immunology
    DW-1350 is a LTB4 receptor antagonist.
    DW-1350
  • HY-117896
    SC-50605

    		Leukotriene Receptor Inflammation/Immunology
    SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .
    SC-50605
  • HY-114641
    BIIL-260

    		Leukotriene Receptor Inflammation/Immunology
    BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM .
    BIIL-260
  • HY-122536
    Ricinelaidic acid

    		Leukotriene Receptor Calcium Channel Endogenous Metabolite Inflammation/Immunology
    Ricinelaidic acid,a 12-hydroxy fatty acid，is a leukotriene B4 (LTB4) receptor antagonist with the Ki of 2 µM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC50values = 10 and 7 µM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .
    Ricinelaidic acid
  • HY-U00263
    LY210073

    		Leukotriene Receptor Inflammation/Immunology
    LY210073 is a Leukotriene B4 (LTB4) receptor antagonist with an IC50 of 6.2 nM.
    LY210073
  • HY-13628A
    Etalocib sodium

    LY293111 sodium; VML 295 sodium

    		 Leukotriene Receptor Apoptosis Inflammation/Immunology Cancer
    Etalocib (LY293111) sodium, an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib sodium prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib sodium induces apoptosis .
    Etalocib sodium
  • HY-131651
    Leukotriene B4 ethanolamide

    LTB4 ethanolamide

    		 Endogenous Metabolite Leukotriene Receptor Cancer
    Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
    Leukotriene B4 ethanolamide
  • HY-19304
    Amelubant

    BIIL 284

    		 Leukotriene Receptor Inflammation/Immunology
    Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .
    Amelubant
  • HY-13628
    Etalocib
    2 Publications Verification

    LY293111; VML 295

    		 Leukotriene Receptor Apoptosis Inflammation/Immunology Cancer
    Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
    Etalocib
  • HY-121621
    RO5101576

    		Endogenous Metabolite Inflammation/Immunology
    RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .
    RO5101576
  • HY-108396
    γ-Linolenic acid ethyl ester

    Ethyl γ-linolenate

    		 Leukotriene Receptor Inflammation/Immunology
    γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .
    γ-Linolenic acid ethyl ester
  • HY-117557
    LY306669

    		Leukotriene Receptor Inflammation/Immunology
    LY306669 is a potent and selective leukotriene B4 (LTB4) receptor antagonist that can be used for the research of lung injury .
    LY306669
  • HY-112742
    CP-195543

    		Leukotriene Receptor Inflammation/Immunology
    CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .
    CP-195543
  • HY-115390
    14,15-Dehydro Leukotriene B4

    		Leukotriene Receptor Cardiovascular Disease Inflammation/Immunology
    14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a Ki value of 27 nM and BLT2 with a Ki value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC50 value of 1 µM .
    14,15-Dehydro Leukotriene B4
  • HY-117706
    LY 292728

    		Leukotriene Receptor Inflammation/Immunology
    LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM .
    LY 292728
  • HY-117854
    SB 201146

    		Leukotriene Receptor Inflammation/Immunology
    SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .
    SB 201146
  • HY-103360
    J-113863
    3 Publications Verification

    		 CCR Inflammation/Immunology
    J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
    J-113863
  • HY-19443
    UCB-35440

    		Histamine Receptor Lipoxygenase Inflammation/Immunology
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .
    UCB-35440

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: